Welcome to 2026, and to an era of FoodTech undoubtedly different than the last. What worked five years ago – the cheap capital, frothy valuations, hype over fundamentals – is long gone. And the market correction is a breath of fresh air; a Darwinian process that leaves the real businesses still standing and poised for growth.
Indeed this year demands what should always be required: real ROI, operational discipline, and technologies solving concrete problems. Before getting sector-specific, let’s start with the macro, because no one operates in a vacuum. We’d be wary of anyone claiming a crystal ball, but there are forces at play that will shape the food industry, FoodTech, and investors in both the immediate term and the long run.
Geographic fragmentation. As investors it’s always important to have a wide lens alongside the sector expertise. On that front, says Founding General Partner Erich Sieber, a further decoupling of Europe and the United States may be in the cards. “There’s a fundamental uncertainty around U.S. policy, including trade, regulation, geopolitics, and industrial policy. That’s creating a growing sense that Europe needs to become more self-sufficient, whether economically, in food security, or defense. And we’d be remiss not to look beyond that prism to Asia, which at some 60% of the global population holds most of the consumers of the future.”
Supply chain breaking points. Among those uncertainties is the global supply chain, still wrangled by tariffs, accompanying logistics shocks, and significant labor shortages. Tariffs have largely made their way out of headlines, but for the food industry it’s still a significant and unfolding event. For FoodTech companies and investors, that can have direct implications on planning a successful go-to-market strategy and risk mitigation. Then there’s volatility across commodities. By now many are familiar stories, some of which we’ve discussed at length: coffee, cocoa, vanilla, palm oil. The forces driving this are long-term structural problems, not random anomalies.
The AI reckoning. It’s safe to say we’re in the most significant technological revolution of our lifetimes. In an environment defined by supply-chain fragility, commodity volatility, and rising execution risk, AI is no longer a nice-to-have. It has transformative applications for the food and health industry, some of which are already being implemented, from cutting food waste to analysis of blood biomarkers. But it has also fogged investors’ lenses with hype and thrown confusion into corporate giants, scrambling to onboard solutions without particularly effective systems to validate or integrate them. This year will demand maturation; proof over promise.
The nutrition and health inflection point. This space is undergoing shifts that should not be underestimated. The core reality we’ve mapped out before still holds true, including spiking global healthcare costs, a growing burden of chronic disease, and the need for solutions that address both. As Partner and CTO Dr. Gali Artzi puts it,
“We need an urgent mindset shift from reactive sick care to proactive health care.” And that’s increasingly what consumers want too: specific, proven solutions for specific needs. The end of general wellness.
Further tailwinds are coming from the regulatory front with the push against ultra-processed foods, now moving beyond statements to state-led action and lawsuits. In the U.S., both California and Texas (on opposite sides of the political divide) are taking the lead, including a landmark lawsuit out of San Francisco targeting some of America’s biggest food manufacturers.
In this broader health reset, the GLP-1 story deserves an extra beat.
The drugs are moving from trendy breakthrough innovation to healthcare infrastructure, and just a week into 2026 the game is changing thanks to prices, and pills.
Oral GLP-1 drugs have hit the American market for the first time. Novo Nordisk is the first of the drug makers to come out with a pill form of the weight loss drugs, available with a prescription across the U.S. Add to that a further price drop on the way, with Eli Lilly and Company’s direct-to-patient model and the public-private partnership ‘TrumpRx’ expected to significantly cut costs for injectables (and presumably soon for pills too).
I don’t normally like to say game changing,” notes Managing Partner Yoni Glickman, “but this truly is. I think cost, easier delivery, and the resulting availability will massively change the uptake of GLPs.” Taken together, this new reality signals true disruption for traditional food corporates, and an opportunity for innovators and
investors who navigate it with discipline.
WHAT TO IGNORE: SAVE YOUR CAPITAL
Each sector undoubtedly has its own gold mines and minefields, but there are some fundamental red flags to steer clear of across the board.
- Unclear ROI. Any company or opportunity that can’t prove true ROI, meaning both economic ROI and clear benefits to the consumer or user, whether it be health, climate or otherwise. This is especially important amid the AI revolution, where AI wrappers and a rush to jump on the bandwagon are leading to ‘solutions’ without genuine business cases or validated ROI.
- Capex-intensive investments. Large-scale Capex build-outs, requiring in some cases $100-$300M to complete, often prove difficult to finance. When such facilities are aimed at producing lower value or even commodity ingredients, attracting the required capital can prove impossible. VCs managing typical closed-end funds will need to find more strategic and creative approaches to fund production assets in food and ingredients, identifying opportunities with better Capex efficiency and higher margin end products.
- Pure sustainability plays. “Better for the planet” is not enough. If there are no cost savings, no measurable performance improvement, and no regulatory pull, customers won’t switch, and corporates won’t pay. The results are nice demos, not businesses.
With that out of the way, let’s look at specific investment areas we’re watching across sectors.
HEALTH & NUTRITION TECH
We continue to believe and invest in the intersection of health, nutrition, health, and technology. Food-as-Medicine solutions and functional nutrition are key categories here, driven by both payer interest (crucial for scaling), and rising consumer interest in metabolic health, aging/longevity and biomarkers.
In particular we see (and expect further) growth in personalized nutrition, functional beverages, and validated probiotics. Winners require clinical evidence and smart navigation of regulation – as a strategy, not an afterthought.
The GLP-1 butterfly effect is also creating distinct investment opportunities. We’ve already seen how these drugs are reshaping category structures, with consumption down and consumers looking for more nutrient-dense and real food options. Population data is in early stages, but an estimated 12% of American adults have taken GLPs. Within six months of starting them, households cut overall grocery spending by 5.3%; fast food was also down, with the steepest declines in calorie-dense, highly processed categories, including a 10.1% drop in savory snacks. 1Oral GLPs will turbocharge all of that.
The resulting opportunities are across two distinct populations: active GLP-1 users and post-GLP users (those in a maintenance phase or off the drug entirely). Active users have specific needs, namely high-protein, satiety foods, gut-hormone-supportive ingredients, and muscle preservation. Those weaning off the drug also represent a huge and underserved market. The risk of regaining weight results in a demand for stabilizing nutrition, precision meal plans, and metabolic support. Relevant categories include companion foods (high protein, low sugar, functional blends), personalized, continuous meal-planning ecosystems, and GLP-1-adjacent bioactives.
What to Ignore
“Functional” without the scientific rigor? Forget it. Think probiotics, mushroom blends and adaptogens with unsupported claims. Without robust clinical data, these are at best great marketing stories, not durable businesses.
DIGITALIZATION & FOOD SYSTEM 4.0
Over the last 7+ years, PeakBridge has built a growing portfolio in this vertical. For good reason: the global food system is plagued by a myriad of pressures and inefficiencies that simply aren’t sustainable in the long term. Now AI has entered the picture as a clear game-changer. But as Founding General Partner Nadav Berger puts it,
“Now is the time for clarity and adoption in applications across the food value chain. How can you build real AI use cases that either increase your growth and sales or lower your costs and make you more efficient?”
One of the food industry’s major costs is linked to supply chain logistics: from sourcing to warehousing, monitoring and processing of materials. Applied AI can improve efficiency while ensuring compliance. But this requires companies to demonstrate ROI in the form of labor reduction, yield gains, reduced downtime, cutting food waste and more.
Another area to watch is what Partner Thomas van den Boezem dubs ‘industrial software.’ Meaning software implemented in production and industrial environments, across food and health care. Business model and go-to-market hurdles may actually prove a source of competitive advantage, explains van den Boezem.
“Once you’ve built a data advantage through deep integration in customers’ systems, switching costs for a customer are high. Investors sometimes struggle to see the opportunity, and benchmarked against horizontal SaaS there are indeed risks: longer sales cycles, multiple levels of integration, and sometimes the installation of specific hardware. This pays off however, with companies ultimately achieving >75% gross margins and recurring revenue growth rates that match their horizontal peers.”
Finally food safety, traceability and compliance tech are also areas where we see significant potential and growth. This will only become more relevant with the FDA’s new traceability rules, aimed at making it easier to track certain foods quickly across the supply chain when contamination or outbreaks hit. Though compliance has been delayed from the original January 2026 date, there are clear implications and needs for better handling of traceability data.
What to Ignore
AI as a moat (when it isn’t). No surprise AI quickly became a must have in every startup deck. In reality, very few have a true AI advantage, and fewer demonstrate repeatable ROI. If the solution doesn’t consistently cut waste, improve yield, or reduce working capital, it’s not a real differentiator.
INGREDIENT INNOVATION
Specialty ingredients have far-reaching potential, particularly right now. That’s because they solve specific problems for manufacturers who have limited alternatives. They integrate into established formulations. And they don’t require consumer marketing or retail distribution build-out. The current convergence of supply chain vulnerability, regulatory pressure on artificial additives and consumer demand for functional health benefits will continue to create significant opportunities here.
On the supply chain side, technologies that can help stabilize the status-quo volatility are key, to redefine how we grow, cultivate, manufacture, supply and use ingredients. Within the PeakBridge portfolio there are several good examples of this, including Vanilla Vida with a vertically integrated operation to create a stable supply of high-quality vanilla, and Win-Win, alternative chocolate that eliminates dependence on cocoa altogether.
The push towards clean label is already transforming the ingredients sector. We all know there’s growing regulatory and consumer pushback against synthetic colors. But the world of so-called ‘natural’ flavors is next in line. As Glickman notes,
“People are going to gradually understand that a natural flavor is made up of 25 different molecules, and you don’t actually know what’s in it. They’re going to want to see, what exactly is in my food?”
This same reality is true for both food colors and flavors – global markets estimated at around $4 billion and $16 billion respectively – that touch nearly everything we eat.2
The future is in real food ingredients, or ‘foodstuff’ in industry terms. Labels every consumer can understand. That might look like beet extract or carob extract, or fermented chickpeas and barley like in The Mediterranean Food Lab’s SHO stocks. The good news? These products often don’t require technology with an excessive Capex stack. “It’s either physical filtration processes or solid-state fermentation,” says Glickman. “We have to build fundamental R&D and there’s still a lot of innovation to be done, but it’s feasible.”
What to Ignore
Precision fermentation for low-value or poorly priced ingredients. Today this technology works technically, but the economics don’t unless the ingredient is high value. That means a Capex and Opex burden, feedstock exposure and pricing challenges. In a nutshell – tough to scale.
ALTERNATIVE PROTEIN TECHNOLOGIES
This sector has had its own series of rude awakenings, topped off by those high-profile closures at the end of the year, including Believer Meats and Meatable. These were areas that showed warning signs from the outset; that’s because building an expensive biological process to produce a commodity-like product has structural economics that are hard to solve. So what’s investible going forward?
Across the board, companies in this sector would do well to view themselves as an ingredient platform. It’s a smart way to move the needle at scale, providing an enabling technology that integrates into existing products, brands, and supply chains, rather than a standalone consumer proposition. This approach enables faster scale, lower capital intensity, potentially faster consumer adoption, and reduced branding risk. Fiber Foods does this well with PrimeJack®, their premium dehydrated jackfruit ingredient made for large-scale food manufacturing.
Above all, alternative protein technologies demand discipline to scale gradually: to first show proof points regarding the technology, product-market fit and regulatory approvals, and only then move to meaningful Capex investments.
What to ignore
You cannot first build it and then assume they will come. In today’s climate of investor caution, that strategy is a red flag; successful plays will first demonstrate product-market fit and sound unit economics before scaling up Capex-intensive infrastructure.
A NOTE FOR THE INNOVATORS
The real stewards of change, turning these opportunities into real-world solutions, are of course the entrepreneurs. And it hasn’t been an easy few years. So what’s one piece of advice we’d offer going into 2026?
Dr. Gali Artzi For us, founders need to focus on progress that’s tangible: real unit economics, real customers, and real operations: not promises. Economics proven in production, customers who pay and return, beyond pilots; and the ability to operate beyond the lab.
Yoni Glickman Even if you think you’ve raised a lot of money, you need to think about your capital. Focus on efficiency every day and run the business like it was yours and not your investors’ money. Ask yourself: what would I do if this was coming out of my own pocket?
Nadav Berger Be mindful of doing due diligence on your potential investors. If they’re at the end of their investment phase and don’t have money, don’t talk to them. If they invest in B2B and you’re B2C, it’s irrelevant. Talk to other startups a VC has invested in. Founders’ time is scarce, so treat it that way.
Thomas van den Boezem If you plan to raise, or raised money from investors, review the investment opportunity through their lens. What needs to hold true for this to be an attractive investment for them? Work back from that outcome to the current status and ask. Is this realistic? What are the key risks? This should lead to a more balanced discussion and better alignment between founders and investors.
Martina Pace Good leadership isn’t about being surprised less, it’s about being prepared more. Force teams to ask the uncomfortable questions early: what could fail, what would it cost, and what’s the fallback? That discipline can be the difference between a temporary setback and running out of cash.
Erich Sieber: I’ll go back to basics, which are just as true for the year ahead. You have to effectively tell your story, to expertly select and motivate your team, and ensure funding or break-even.
ENDNOTES
- The White House, “Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most Favored Nation Pricing to American Patients,” Nov. 2025, https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/; OneDigital, “New Pricing Agreements for Popular Weight Loss Drugs,” https://www.onedigital.com/blog/new-pricing-agreements-popular-weight-loss-drugs/.
- “The Impact of GLP-1 Receptor Agonists on Food and Beverage Consumption: Evidence from Consumer Panel Data,” Journal of Marketing, https://journals.sagepub.com/doi/10.1177/00222437251412834; RAND Corporation, “The Projected Impact of GLP-1 Agonists on Obesity Prevalence by 2050,” Research Reports, https://www.rand.org/pubs/research_reports/RRA4153-1.html.